Press Release / Dec 04, 2017
Hovione Announces Enrollment of First Patient in MARS
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation
C&EN, 8 June, 2009
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.